Workflow
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
百时美施贵宝百时美施贵宝(US:BMY) ZACKS·2025-10-27 22:21

Key Takeaways Bristol-Myers Squibb reports Q3 2025 results on Oct. 30, with sales seen at 11.83billion.StrongdemandforOpdivo,CamzyosandReblozyllikelysupportedthegrowthportfolio.GenericpressureonEliquis,RevlimidandPomalystmayhaveweighedonoverallrevenues.BiotechgiantBristol−MyersSquibbCompany(BMY)isscheduledtoreportthird−quarter2025resultsonOct.30,beforemarketopen.TheZacksConsensusEstimateforsalesandearningsispeggedat11.83 billion.Strong demand for Opdivo, Camzyos and Reblozyl likely supported the growth portfolio.Generic pressure on Eliquis, Revlimid and Pomalyst may have weighed on overall revenues.Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report third-quarter 2025 results on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at 11.83 billion and $1.51 per share, re ...